Northern Trust Corp Buys 102,011 Shares of Repligen Co. (NASDAQ:RGEN)

Northern Trust Corp boosted its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 26.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 493,713 shares of the biotechnology company's stock after purchasing an additional 102,011 shares during the quarter. Northern Trust Corp owned about 0.88% of Repligen worth $71,065,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its holdings in Repligen by 11.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock valued at $1,027,165,000 after purchasing an additional 743,815 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Repligen by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock worth $734,251,000 after acquiring an additional 56,723 shares in the last quarter. Champlain Investment Partners LLC lifted its holdings in Repligen by 8.6% during the fourth quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock worth $222,176,000 after acquiring an additional 122,595 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Repligen by 23.4% in the fourth quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock valued at $145,508,000 after purchasing an additional 191,439 shares in the last quarter. Finally, Conestoga Capital Advisors LLC lifted its holdings in shares of Repligen by 0.7% in the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company's stock valued at $136,395,000 after purchasing an additional 6,872 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Price Performance

Shares of RGEN stock traded down $4.61 during trading hours on Friday, reaching $123.24. The company's stock had a trading volume of 580,989 shares, compared to its average volume of 727,651. The firm's 50 day simple moving average is $135.03 and its 200-day simple moving average is $145.44. The company has a market capitalization of $6.92 billion, a price-to-earnings ratio of -241.65, a PEG ratio of 4.54 and a beta of 1.21. Repligen Co. has a fifty-two week low of $102.97 and a fifty-two week high of $182.52. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $169.17 million for the quarter, compared to the consensus estimate of $163.65 million. During the same quarter last year, the business posted $0.28 EPS. The company's revenue was up 10.4% compared to the same quarter last year. Sell-side analysts forecast that Repligen Co. will post 1.72 earnings per share for the current year.

Insider Activity at Repligen

In other news, Director Margaret Pax acquired 250 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now directly owns 1,043 shares in the company, valued at $157,169.67. The trade was a 31.53% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 1.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on RGEN. TD Cowen began coverage on Repligen in a research report on Monday, February 10th. They issued a "buy" rating and a $200.00 target price on the stock. Evercore ISI began coverage on Repligen in a research report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 target price on the stock. Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target on the stock in a research report on Tuesday, April 29th. StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a research report on Thursday. Finally, JPMorgan Chase & Co. decreased their target price on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 29th. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $173.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.